Showing results (441-450 of 464) with videos related to

Sort By:
Pageof 47
Prostate Cancer and Prostatic Diseases|February 28, 2024
Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient OutcomesNicholas A Zorko, Allison Makovec, Andrew Elliott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 24, 2017
First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid TumorsMark N Stein, Joseph R Bertino, Howard L Kaufman, et al.
The Journal of Clinical Investigation|January 14, 2025
TRAIL agonists rescue mice from radiation-induced lung, skin, or esophageal injuryJillian Strandberg, Anna Louie, Seulki Lee, et al.
Neoplasia (New York, N.Y.)|November 3, 2020
ONC201 and imipridones: Anti-cancer compounds with clinical efficacyVarun Vijay Prabhu, Sara Morrow, Abed Rahman Kawakibi, et al.
NPJ Precision Oncology|July 3, 2023
PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair systemKai Zimmer, Florian Kocher, Gerold Untergasser, et al.
The Journal of Investigative Dermatology|March 22, 2003
Stroma formation and angiogenesis by overexpression of growth factors, cytokines, and proteolytic enzymes in human skin grafted to SCID miceClaus J Gruss, Kapaettu Satyamoorthy, Carola Berking, et al.
JCO Oncology Advances|May 7, 2025
Molecular Characterization and Clinical Outcomes of Pancreatic Neuroendocrine Neoplasms Harboring PAK4-NAMPT AlterationsIbrahim Azar, Husain Yar Khan, Sahar F Bannoura, et al.
Cancer Discovery|October 31, 2020
Netrin G1 Promotes Pancreatic Tumorigenesis through Cancer-Associated Fibroblast-Driven Nutritional Support and ImmunosuppressionRalph Francescone, Débora Barbosa Vendramini-Costa, Janusz Franco-Barraza, et al.
Oncotarget|October 22, 2021
Correction: Discovery and clinical introduction of first-in-class imipridone ONC201Joshua E Allen, C Leah B Kline, Varun V Prabhu, et al.
Pageof 47